PASI-75 and PASI-90 responder rates at weeks 4, 12, 24, and 52.... | Download Scientific Diagram
What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis - Practical Dermatology
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial - ScienceDirect
Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan | PLOS ONE
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal
Pediatric PsO Treatment Information | COSENTYX® (secukinumab) | HCP
Skin Clearance | Efficacy | RINVOQ® (upadacitinib)
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomize
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Moderate to severe plaque psoriasis | CIMZIA® (certolizumab pegol)
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial* - Augustin -
NNTs show once-unimaginable psoriasis outcomes now readily attainable | MDedge Rheumatology
Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) | HTML | Acta Dermato-Venereologica
Mapping Psoriasis Endpoints: beyond the mirage of complete skin clearance
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis - European Medical Journal
Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials -
PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram
SIMPONI ARIA® Psoriatic Arthritis Efficacy: PASI Response | HCP
